

Supplementary materials: New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents

Ilya A. Shutkov, Yulia N. Okulova, Dmitrii M. Mazur, Nikolai A. Melnichuk, Denis A. Babkov, Elena V. Sokolova, Alexander A. Spasov, Elena R. Milaeva and Alexey A. Nazarov








Figure S1. Experimental spectrum for complex 15, simulated spectrum for $[M+H]^+$, simulated spectrum for $[M+Na]^+$.



Experimental mass spectrum



Simulated mass spectrum of $[M+H]^+$ specie



Simulated mass spectrum of $[M+Na]^+$ specie

Figure S2. Experimental spectrum for complex 16, simulated spectrum for $[M+H]^+$, simulated spectrum for $[M+Na]^+$.





Figure S3. Experimental spectrum for complex 17, simulated spectrum for $[M+H]^+$, simulated spectrum for $[M+Na]^+$.





Figure S4. Experimental spectrum for complex 18, simulated spectrum for $[M-Cl]^+$





Figure S5. Experimental spectrum for complex **19**, simulated spectrum for [M-Cl]⁺.




Figure S6. Signal shifts in ¹H NMR spectra of ligand 5 and complexes 11, 14.